Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 317


Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells.

Ciardullo C, Aptullahoglu E, Woodhouse L, Lin WY, Wallis JP, Marr H, Marshall S, Bown N, Willmore E, Lunec J.

Haematologica. 2019 Dec;104(12):2429-2442. doi: 10.3324/haematol.2018.206631. Epub 2019 Apr 19.


TP53 mutant cell lines selected for resistance to MDM2 inhibitors retain growth inhibition by MAPK pathway inhibitors but a reduced apoptotic response.

Wu CE, Koay TS, Ho YH, Lovat P, Lunec J.

Cancer Cell Int. 2019 Mar 7;19:53. doi: 10.1186/s12935-019-0768-3. eCollection 2019.


Nucleotide variants and protein expression of TP53 in a Sri Lankan cohort of patients with head and neck cancer.

Manoharan V, Karunanayake EH, Tennekoon KH, De Silva S, De Silva K, Angunawela P, Lunec J.

Mol Med Rep. 2019 Apr;19(4):2781-2791. doi: 10.3892/mmr.2019.9948. Epub 2019 Feb 11.


ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma.

Wu CE, Koay TS, Esfandiari A, Ho YH, Lovat P, Lunec J.

Cancers (Basel). 2018 Dec 20;11(1). pii: E3. doi: 10.3390/cancers11010003.


Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma.

Chen L, Pastorino F, Berry P, Bonner J, Kirk C, Wood KM, Thomas HD, Zhao Y, Daga A, Veal GJ, Lunec J, Newell DR, Ponzoni M, Tweddle DA.

Int J Cancer. 2019 Jun 15;144(12):3146-3159. doi: 10.1002/ijc.32058. Epub 2019 Jan 9.


Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor.

Franklin M, Gentles L, Matheson E, Bown N, Cross P, Ralte A, Gilkes-Immeson C, Bradbury A, Zanjirband M, Lunec J, Drew Y, O'Donnell R, Curtin NJ.

Cancer Med. 2018 Sep;7(9):4744-4754. doi: 10.1002/cam4.1724. Epub 2018 Aug 14.


Highly Potent Clickable Probe for Cellular Imaging of MDM2 and Assessing Dynamic Responses to MDM2-p53 Inhibition.

Lebraud H, Noble RA, Phillips N, Heam K, Castro J, Zhao Y, Newell DR, Lunec J, Wedge SR, Heightman TD.

Bioconjug Chem. 2018 Jun 20;29(6):2100-2106. doi: 10.1021/acs.bioconjchem.8b00315. Epub 2018 Jun 12.


Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.

Ladds MJGW, van Leeuwen IMM, Drummond CJ, Chu S, Healy AR, Popova G, Pastor Fernández A, Mollick T, Darekar S, Sedimbi SK, Nekulova M, Sachweh MCC, Campbell J, Higgins M, Tuck C, Popa M, Safont MM, Gelebart P, Fandalyuk Z, Thompson AM, Svensson R, Gustavsson AL, Johansson L, Färnegårdh K, Yngve U, Saleh A, Haraldsson M, D'Hollander ACA, Franco M, Zhao Y, Håkansson M, Walse B, Larsson K, Peat EM, Pelechano V, Lunec J, Vojtesek B, Carmena M, Earnshaw WC, McCarthy AR, Westwood NJ, Arsenian-Henriksson M, Lane DP, Bhatia R, McCormack E, Laín S.

Nat Commun. 2018 May 22;9(1):2071. doi: 10.1038/s41467-018-04198-5.


A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.

Ladds MJGW, van Leeuwen IMM, Drummond CJ, Chu S, Healy AR, Popova G, Pastor Fernández A, Mollick T, Darekar S, Sedimbi SK, Nekulova M, Sachweh MCC, Campbell J, Higgins M, Tuck C, Popa M, Safont MM, Gelebart P, Fandalyuk Z, Thompson AM, Svensson R, Gustavsson AL, Johansson L, Färnegårdh K, Yngve U, Saleh A, Haraldsson M, D'Hollander ACA, Franco M, Zhao Y, Håkansson M, Walse B, Larsson K, Peat EM, Pelechano V, Lunec J, Vojtesek B, Carmena M, Earnshaw WC, McCarthy AR, Westwood NJ, Arsenian-Henriksson M, Lane DP, Bhatia R, McCormack E, Laín S.

Nat Commun. 2018 Mar 16;9(1):1107. doi: 10.1038/s41467-018-03441-3. Erratum in: Nat Commun. 2018 May 22;9(1):2071.


Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours.

Chen L, Esfandiari A, Reaves W, Vu A, Hogarty MD, Lunec J, Tweddle DA.

Int J Oncol. 2018 Mar;52(3):967-977. doi: 10.3892/ijo.2018.4261. Epub 2018 Jan 31.


Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.

Wu CE, Esfandiari A, Ho YH, Wang N, Mahdi AK, Aptullahoglu E, Lovat P, Lunec J.

Br J Cancer. 2018 Feb 20;118(4):495-508. doi: 10.1038/bjc.2017.433. Epub 2017 Dec 12.


Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer.

Zanjirband M, Curtin N, Edmondson RJ, Lunec J.

Oncotarget. 2017 Jul 15;8(41):69779-69796. doi: 10.18632/oncotarget.19266. eCollection 2017 Sep 19.


Multi-walled carbon nanotubes: A cytotoxicity study in relation to functionalization, dose and dispersion.

Zhou L, Forman HJ, Ge Y, Lunec J.

Toxicol In Vitro. 2017 Aug;42:292-298. doi: 10.1016/j.tiv.2017.04.027. Epub 2017 May 5.


Functional characterisation of a novel ovarian cancer cell line, NUOC-1.

McCormick A, Earp E, Elliot K, Cuthbert G, O'Donnell R, Wilson BT, Sutton R, Leeson C, Thomas HD, Blair H, Fordham S, Lunec J, Allan J, Edmondson RJ.

Oncotarget. 2017 Apr 18;8(16):26832-26844. doi: 10.18632/oncotarget.15821.


Nutlin-3 inhibits androgen receptor-driven c-FLIP expression, resulting in apoptosis of prostate cancer cells.

Logan IR, McClurg UL, Jones DL, O'Neill DJ, Shaheen FS, Lunec J, Gaughan L, Robson CN.

Oncotarget. 2016 Nov 15;7(46):74724-74733. doi: 10.18632/oncotarget.12542.


TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation.

Drummond CJ, Esfandiari A, Liu J, Lu X, Hutton C, Jackson J, Bennaceur K, Xu Q, Makimanejavali AR, Del Bello F, Piergentili A, Newell DR, Hardcastle IR, Griffin RJ, Lunec J.

Oncotarget. 2016 Jul 19;7(29):46203-46218. doi: 10.18632/oncotarget.10073.


Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis: Mechanism and Potential Role for PARP Inhibitors.

Kotsopoulos IC, Kucukmetin A, Mukhopadhyay A, Lunec J, Curtin NJ.

Int J Gynecol Cancer. 2016 May;26(4):763-9. doi: 10.1097/IGC.0000000000000654. Review.


Surgical outcome and patterns of recurrence for retroperitoneal sarcoma at a single centre.

Hogg HD, Manas DM, Lee D, Dildey P, Scott J, Lunec J, French JJ.

Ann R Coll Surg Engl. 2016 Mar;98(3):192-7. doi: 10.1308/rcsann.2016.0057. Epub 2016 Feb 14.


Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.

Esfandiari A, Hawthorne TA, Nakjang S, Lunec J.

Mol Cancer Ther. 2016 Mar;15(3):379-91. doi: 10.1158/1535-7163.MCT-15-0651. Epub 2016 Feb 1.


PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia.

Herriott A, Tudhope SJ, Junge G, Rodrigues N, Patterson MJ, Woodhouse L, Lunec J, Hunter JE, Mulligan EA, Cole M, Allinson LM, Wallis JP, Marshall S, Wang E, Curtin NJ, Willmore E.

Oncotarget. 2015 Dec 22;6(41):43978-91. doi: 10.18632/oncotarget.6287.


Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma.

Chen L, Rousseau RF, Middleton SA, Nichols GL, Newell DR, Lunec J, Tweddle DA.

Oncotarget. 2015 Apr 30;6(12):10207-21.


Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker.

Ramlau R, Thomas M, Novello S, Plummer R, Reck M, Kaneko T, Lau MR, Margetts J, Lunec J, Nutt J, Scagliotti GV.

Clin Lung Cancer. 2015 Sep;16(5):348-57. doi: 10.1016/j.cllc.2015.01.004. Epub 2015 Jan 20.


Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach.

Zaytsev A, Dodd B, Magnani M, Ghiron C, Golding BT, Griffin RJ, Liu J, Lu X, Micco I, Newell DR, Padova A, Robertson G, Lunec J, Hardcastle IR.

Chem Biol Drug Des. 2015 Aug;86(2):180-9. doi: 10.1111/cbdd.12474. Epub 2014 Dec 19.


Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification.

Defferrari R, Mazzocco K, Ambros IM, Ambros PF, Bedwell C, Beiske K, Bénard J, Berbegall AP, Bown N, Combaret V, Couturier J, Erminio G, Gambini C, Garaventa A, Gross N, Haupt R, Kohler J, Jeison M, Lunec J, Marques B, Martinsson T, Noguera R, Parodi S, Schleiermacher G, Tweddle DA, Valent A, Van Roy N, Vicha A, Villamon E, Tonini GP.

Br J Cancer. 2015 Jan 20;112(2):290-5. doi: 10.1038/bjc.2014.557. Epub 2014 Nov 4.


Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastoma.

Chen L, Zhao Y, Halliday GC, Berry P, Rousseau RF, Middleton SA, Nichols GL, Del Bello F, Piergentili A, Newell DR, Lunec J, Tweddle DA.

Br J Cancer. 2014 Aug 12;111(4):716-25. doi: 10.1038/bjc.2014.325. Epub 2014 Jun 12.


COX2 expression in neuroblastoma increases tumorigenicity but does not affect cell death in response to the COX2 inhibitor celecoxib.

Bell E, Ponthan F, Whitworth C, Tweddle DA, Lunec J, Redfern CP.

Clin Exp Metastasis. 2014 Aug;31(6):651-9. doi: 10.1007/s10585-014-9656-3. Epub 2014 May 25.


The clinical development of p53-reactivating drugs in sarcomas - charting future therapeutic approaches and understanding the clinical molecular toxicology of Nutlins.

Biswas S, Killick E, Jochemsen AG, Lunec J.

Expert Opin Investig Drugs. 2014 May;23(5):629-45. doi: 10.1517/13543784.2014.892924. Epub 2014 Feb 28. Review.


An in silico study of the differential effect of oxidation on two biologically relevant G-quadruplexes: possible implications in oncogene expression.

Stebbeds WJ, Lunec J, Larcombe LD.

PLoS One. 2012;7(8):e43735. doi: 10.1371/journal.pone.0043735. Epub 2012 Aug 22.


Identification and characterisation of STMN4 and ROBO2 gene involvement in neuroblastoma cell differentiation.

Sung PJ, Boulos N, Tilby MJ, Andrews WD, Newbold RF, Tweddle DA, Lunec J.

Cancer Lett. 2013 Jan 1;328(1):168-75. doi: 10.1016/j.canlet.2012.08.015. Epub 2012 Aug 17.


Non-glucose metabolism in cancer cells--is it all in the fat?

Biswas S, Lunec J, Bartlett K.

Cancer Metastasis Rev. 2012 Dec;31(3-4):689-98. doi: 10.1007/s10555-012-9384-6. Review.


Recombinant human MDM2 oncoprotein shows sequence composition selectivity for binding to both RNA and DNA.

Challen C, Anderson JJ, Chrzanowska-Lightowlers ZM, Lightowlers RN, Lunec J.

Int J Oncol. 2012 Mar;40(3):851-9. doi: 10.3892/ijo.2011.1267. Epub 2011 Nov 21.


Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression.

Carr-Wilkinson J, Griffiths R, Elston R, Gamble LD, Goranov B, Redfern CP, Lunec J, Tweddle DA.

Cell Cycle. 2011 Nov 1;10(21):3778-87. doi: 10.4161/cc.10.21.17973. Epub 2011 Nov 1.


Of dogs and men: comparative biology as a tool for the discovery of novel biomarkers and drug development targets in osteosarcoma.

Rankin KS, Starkey M, Lunec J, Gerrand CH, Murphy S, Biswas S.

Pediatr Blood Cancer. 2012 Mar;58(3):327-33. doi: 10.1002/pbc.23341. Epub 2011 Oct 11. Review.


MDM2-p53 protein-protein interaction inhibitors: a-ring substituted isoindolinones.

Watson AF, Liu J, Bennaceur K, Drummond CJ, Endicott JA, Golding BT, Griffin RJ, Haggerty K, Lu X, McDonnell JM, Newell DR, Noble ME, Revill CH, Riedinger C, Xu Q, Zhao Y, Lunec J, Hardcastle IR.

Bioorg Med Chem Lett. 2011 Oct 1;21(19):5916-9. doi: 10.1016/j.bmcl.2011.07.084. Epub 2011 Aug 9.


MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.

Gamble LD, Kees UR, Tweddle DA, Lunec J.

Oncogene. 2012 Feb 9;31(6):752-63. doi: 10.1038/onc.2011.270. Epub 2011 Jul 4.


A multilocus technique for risk evaluation of patients with neuroblastoma.

Ambros IM, Brunner B, Aigner G, Bedwell C, Beiske K, Bénard J, Bown N, Combaret V, Couturier J, Defferrari R, Gross N, Jeison M, Lunec J, Marques B, Martinsson T, Mazzocco K, Noguera R, Schleiermacher G, Speleman F, Stallings R, Tonini GP, Tweddle DA, Valent A, Vicha A, Roy NV, Villamon E, Ziegler A, Preuner S, Drobics M, Ladenstein R, Amann G, Schuit RJ, Pötschger U, Ambros PF.

Clin Cancer Res. 2011 Feb 15;17(4):792-804. doi: 10.1158/1078-0432.CCR-10-0830.


Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency.

Hardcastle IR, Liu J, Valeur E, Watson A, Ahmed SU, Blackburn TJ, Bennaceur K, Clegg W, Drummond C, Endicott JA, Golding BT, Griffin RJ, Gruber J, Haggerty K, Harrington RW, Hutton C, Kemp S, Lu X, McDonnell JM, Newell DR, Noble ME, Payne SL, Revill CH, Riedinger C, Xu Q, Lunec J.

J Med Chem. 2011 Mar 10;54(5):1233-43. doi: 10.1021/jm1011929. Epub 2011 Feb 11.


MYCN oncoprotein targets and their therapeutic potential.

Bell E, Chen L, Liu T, Marshall GM, Lunec J, Tweddle DA.

Cancer Lett. 2010 Jul 28;293(2):144-57. doi: 10.1016/j.canlet.2010.01.015. Epub 2010 Feb 13. Review.


High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma.

Carr-Wilkinson J, O'Toole K, Wood KM, Challen CC, Baker AG, Board JR, Evans L, Cole M, Cheung NK, Boos J, Köhler G, Leuschner I, Pearson AD, Lunec J, Tweddle DA.

Clin Cancer Res. 2010 Feb 15;16(4):1108-18. doi: 10.1158/1078-0432.CCR-09-1865. Epub 2010 Feb 9.


p53 is a direct transcriptional target of MYCN in neuroblastoma.

Chen L, Iraci N, Gherardi S, Gamble LD, Wood KM, Perini G, Lunec J, Tweddle DA.

Cancer Res. 2010 Feb 15;70(4):1377-88. doi: 10.1158/0008-5472.CAN-09-2598. Epub 2010 Feb 9.


The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy.

Nutt JE, Razak AR, O'Toole K, Black F, Quinn AE, Calvert AH, Plummer ER, Lunec J.

Br J Cancer. 2010 Feb 2;102(3):553-60. doi: 10.1038/sj.bjc.6605501. Epub 2010 Jan 5.


A monoclonal antibody for detection of folylpolyglutamate synthetase in paraffin embedded tissues.

Quinn AE, Pinkney M, Piggott NH, Calvert H, Milton ID, Lunec J.

Hybridoma (Larchmt). 2009 Dec;28(6):415-21. doi: 10.1089/hyb.2009.0040.


Can vitamin C induce nucleotide excision repair? Support from in vitro evidence.

Bevan RJ, Mistry N, Patel PR, Halligan EP, Dove R, Lunec J.

Br J Nutr. 2010 Mar;103(5):686-95. doi: 10.1017/S0007114509992285. Epub 2009 Dec 10.


Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines.

Nutt JE, O'Toole K, Gonzalez D, Lunec J.

Eur J Cancer. 2009 Jun;45(9):1684-91. doi: 10.1016/j.ejca.2009.02.022. Epub 2009 Mar 25.


Heat shock factor-1 modulates p53 activity in the transcriptional response to DNA damage.

Logan IR, McNeill HV, Cook S, Lu X, Meek DW, Fuller-Pace FV, Lunec J, Robson CN.

Nucleic Acids Res. 2009 May;37(9):2962-73. doi: 10.1093/nar/gkp180. Epub 2009 Mar 18.


Multicenter study to assess potential hazards from exposure to lipid peroxidation products in soya bean oil from Trilucent breast implants.

Williams GM, Caldwell J, Armstrong D, Bartsch H, Bevan R, Browne RW, Chipman JK, Iatropoulos MJ, Jeffrey AM, Lunec J, Nair J, Page DL, Reeves BC, Richardson A, Silverstein B, Williams DF.

Regul Toxicol Pharmacol. 2009 Mar;53(2):107-20. doi: 10.1016/j.yrtph.2008.10.009. Epub 2008 Nov 7.


In vivo vitamin C supplementation increases phosphoinositol transfer protein expression in peripheral blood mononuclear cells from healthy individuals.

Griffiths HR, Willetts RS, Grant MM, Mistry N, Lunec J, Bevan RJ.

Br J Nutr. 2009 May;101(10):1432-9. doi: 10.1017/S0007114508079646. Epub 2008 Oct 24.


Histological profile of tumours from MYCN transgenic mice.

Moore HC, Wood KM, Jackson MS, Lastowska MA, Hall D, Imrie H, Redfern CP, Lovat PE, Ponthan F, O'Toole K, Lunec J, Tweddle DA.

J Clin Pathol. 2008 Oct;61(10):1098-103. doi: 10.1136/jcp.2007.054627. Epub 2008 Aug 4.


Supplemental Content

Support Center